Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric Cancer
Application based on DESTINY-Gastric01 and DESTINY-Gastric02 phase 2 trials TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Company,…